Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of IPI-504 versus placebo in advanced GIST after imatinib and sunitinib failure
NL-OMON34005Phase 3Withdrawn
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of retaspimycin in gastrointestinal stromal tumor (GIST), sponsored by Infinity Pharmaceuticals, Inc.. Planned start Feb 2009; status: withdrawn.
02
Drugs
retaspimycin
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON34005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34005.